Company / Shareholders' Equity
PROKIDNEY CORP. Shareholders' Equity History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$995.0M
FY2024
5-year range
-$1.1B / $26.9M
FY2020-FY2024
Trend
+9.8%
vs FY2023
Sector context
#211 of 213
Health Care
What the data says
PROKIDNEY CORP. reports negative total equity of -$995M in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$995M in FY2024.
Improved from -$1.1B to -$995M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 213This company -$995.0M Sector average $2.5B
▼
-139.0% below sector average
Key checks
Key Insights
- In FY2024, shareholders' equity increased 9.8% year-over-year.
- Ranks #211 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.00 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$995.0M | +9.8% |
| FY2023 | -$1.1B | -0.6% |
| FY2022 | -$1.1B | -4174.1% |
| FY2021 | $26.9M | +172.9% |
| FY2020 | $9.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026